Cited by 202Genetic Syndromes and ImprintingCancer-related molecular mechanisms researchGenomics and Chromatin Dynamics

Ube3a-ATS is an atypical RNA polymerase II transcript that represses the paternal expression of Ube3a

Open access
Meng, Linyan, Person, Richard E., Beaudet, Arthur L.·2012·Human Molecular Genetics

Abstract

The Angelman syndrome gene, UBE3A, is subject to genomic imprinting controlled by mechanisms that are only partially understood. Its antisense transcript, UBE3A-ATS, is also imprinted and hypothesized to suppress UBE3A in cis. In this research, we showed that the mouse antisense ortholog, Ube3a-ATS, was transcribed by RNA polymerase (RNAP) II. However, unlike typical protein-coding transcripts, Ube3a-ATS was not poly-adenylated and was localized exclusively in the nucleus. It was relatively unstable with a half-life of 4 h, shorter than most protein-coding RNAs tested. To understand the role of Ube3a-ATS in vivo, a mouse model with a 0.9-kb genomic deletion over the paternal Snrpn major promoter was studied. The mice showed partial activation of paternal Ube3a, with decreased expression of Ube3a-ATS but not any imprinting defects in the Prader-Willi syndrome/Angelman syndrome region. A novel cell culture model was also generated with a transcriptional termination cassette inserted downstream of Ube3a on the paternal chromosome to reduce Ube3a-ATS transcription. In neuronally differentiated embryonic stem (ES) cells, paternal Ube3a was found to be expressed at a high level, comparable with that of the maternal allele. To further characterize the antisense RNA, a strand-specific microarray was performed. Ube3a-ATS was detectable across the entire locus of Ube3a and extended beyond the transcriptional start site of Ube3a. In summary, we conclude that Ube3a-ATS is an atypical RNAPII transcript that represses Ube3a on the paternal chromosome. These results suggest that the repression of human UBE3A-ATS may activate the expression of UBE3A from the paternal chromosome, providing a potential therapeutic strategy for patients with Angelman syndrome.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/hmg/dds130

Cites

48 of 48 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Maternal deletion of a single imprinted, maternally expressed gene encoding UBE3A on 15q11-q13 gives rise to the Angelman syndrome phenotype.

    “Similarly, paternal-specific deletion of multiple imprinted, paternally expressed genes on the 15q11–q13 region results in Prader–Willi syndrome, whereas maternal deletion of a single, imprinted, maternally expressed gene encoding a ubiquitin-protein ligase (UBE3A) on this same region gives rise to the Angelman syndrome phenotype.”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Meng, L., Person, R. E., & Beaudet, A. L.
Affiliations
Baylor College of Medicine (US)
Corresponding author
Beaudet, Arthur L.
Venue
Human Molecular Genetics
Published
2012-04-05
Volume
21
Issue
13
Pages
3001-3012
ISSN
  • 0964-6906 (ISSN-L)
  • 1460-2083
OpenAlex
W2155623567
Cited by
202
References
48
Citations by year
2026: 16 · 2025: 10 · 2024: 17 · 2023: 11 · 2022: 13 · 2021: 11 · 2020: 22 · 2019: 13 · 2018: 8 · 2017: 7 · 2016: 16 · 2015: 16 · 2014: 23 · 2013: 15 · 2012: 4
FWCI
11.14
Type
journal article
Language
en
Open access
Locations
  • Human Molecular Genetics (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Intellectual and Developmental Disabilities Research Center
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development (R01HD037283)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Syndromes and Imprinting
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer-related molecular mechanisms research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
Keywords
UBE3A, genomic imprinting, antisense RNA, RNA polymerase II, paternal gene expression, Angelman syndrome, Prader-Willi syndrome, RNA stability, transcription termination, embryonic stem cells, treatment options
MeSH terms
Animals, Cells, Cultured, Female, Humans, Male, Mice, Inbred C57BL, Neurons, Promoter Regions, Genetic, RNA Polymerase II, Transcription, Genetic, RNA, Antisense, Angelman Syndrome, Genomic Imprinting, Polyadenylation, Ubiquitin-Protein Ligases, Mice, Embryonic Stem Cells, snRNP Core Proteins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review